The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

A week after a study showed that Vytorin is no more effective in reducing cholesterol than the company’s generic equivalent, Merck and Schering-Plough withdrew their direct-to-consumer marketing ads. Vytorin, a combination of Zetia and Merck’s Zocor, lost patent protection in 2006. The marketing campaign was a familiar one to television viewers and was dubbed “food and family” depicting in a light-hearted fashion how heredity and eating habits can affect a person’s cholesterol. However, the marketing campaign never mentioned any risks or the fact that its generic equivalent was at the very least, as effective as the expensive Vytorin.

For more information on this subject, please refer to the section on Drugs, Medical Devices and Implants.

Comments are closed.

Of Interest